Instruct-ERIC part of the European Strategy Forum on Research infrastructures (ESFRI) (PID: 22183)
European Union
Research Foundation - Flanders (FWO)
ベルギー
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)
NS003139
米国
引用
ジャーナル: Sci Adv / 年: 2025 タイトル: Molecular basis of pyruvate transport and inhibition of the human mitochondrial pyruvate carrier. 著者: Maximilian Sichrovsky / Denis Lacabanne / Jonathan J Ruprecht / Jessica J Rana / Klaudia Stanik / Mariangela Dionysopoulou / Alice P Sowton / Martin S King / Scott A Jones / Lee Cooper / ...著者: Maximilian Sichrovsky / Denis Lacabanne / Jonathan J Ruprecht / Jessica J Rana / Klaudia Stanik / Mariangela Dionysopoulou / Alice P Sowton / Martin S King / Scott A Jones / Lee Cooper / Steven W Hardwick / Giulia Paris / Dimitri Y Chirgadze / Shujing Ding / Ian M Fearnley / Shane M Palmer / Els Pardon / Jan Steyaert / Vanessa Leone / Lucy R Forrest / Sotiria Tavoulari / Edmund R S Kunji / 要旨: The mitochondrial pyruvate carrier transports pyruvate, produced by glycolysis from sugar molecules, into the mitochondrial matrix, as a crucial transport step in eukaryotic energy metabolism. The ...The mitochondrial pyruvate carrier transports pyruvate, produced by glycolysis from sugar molecules, into the mitochondrial matrix, as a crucial transport step in eukaryotic energy metabolism. The carrier is a drug target for the treatment of cancers, diabetes mellitus, neurodegeneration, and metabolic dysfunction-associated steatotic liver disease. We have solved the structure of the human MPC1L/MPC2 heterodimer in the inward- and outward-open states by cryo-electron microscopy, revealing its alternating access rocker-switch mechanism. The carrier has a central binding site for pyruvate, which contains an essential lysine and histidine residue, important for its ΔpH-dependent transport mechanism. We have also determined the binding poses of three chemically distinct inhibitor classes, which exploit the same binding site in the outward-open state by mimicking pyruvate interactions and by using aromatic stacking interactions.
全体 : Complex of human mitochondrial pyruvate carrier (MPC1L/MPC2) inhi...
全体
名称: Complex of human mitochondrial pyruvate carrier (MPC1L/MPC2) inhibited by mitoglitazone with a pro-macrobody
要素
複合体: Complex of human mitochondrial pyruvate carrier (MPC1L/MPC2) inhibited by mitoglitazone with a pro-macrobody
複合体: Mitochondrial pyruvate carrier (MPC1L/MPC2)
タンパク質・ペプチド: Mitochondrial pyruvate carrier 1-like protein
タンパク質・ペプチド: Mitochondrial pyruvate carrier 2
複合体: Macrobody with C-terminal MBP tag
タンパク質・ペプチド: Macrobody,Maltose/maltodextrin-binding periplasmic protein
リガンド: Mitoglitazone
リガンド: Mitoglitazone (R-form)
-
超分子 #1: Complex of human mitochondrial pyruvate carrier (MPC1L/MPC2) inhi...
超分子
名称: Complex of human mitochondrial pyruvate carrier (MPC1L/MPC2) inhibited by mitoglitazone with a pro-macrobody タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#3
分子 #3: Macrobody,Maltose/maltodextrin-binding periplasmic protein
分子
名称: Macrobody,Maltose/maltodextrin-binding periplasmic protein タイプ: protein_or_peptide / ID: 3 詳細: Pro-macrobody is a MBP-nanobody-MBP fusion protein with a 3C protease-cleavable tag between the N-terminal MBP and nanobody. Sequence shows final purified protein post cleavage.,Pro-macrobody ...詳細: Pro-macrobody is a MBP-nanobody-MBP fusion protein with a 3C protease-cleavable tag between the N-terminal MBP and nanobody. Sequence shows final purified protein post cleavage.,Pro-macrobody is a MBP-nanobody-MBP fusion protein with a 3C protease-cleavable tag between the N-terminal MBP and nanobody. Sequence shows final purified protein post cleavage. コピー数: 1 / 光学異性体: LEVO